Abstract
Many difficult-to-treat clinical entities in the cardiovascular field are characterized by pronounced sympathetic overactivity, including resistant hypertension and heart failure, underlining the need to explore therapeutic options beyond pharmacotherapy. Autonomic modulation via carotid baroreceptor activation has already been evaluated in clinical trials for resistant hypertension, and relevant outcomes with regard to safety and efficacy of the technique are critically presented. The pathophysiological background of heart failure renders carotid baroreceptor stimulation a potential treatment candidate for the disease. Available data from animal models with heart failure point towards significant cardioprotective benefits of this innovative technique. Accordingly, the effects of baroreceptor activation treatment (BAT) on cardiac parameters of hypertensive patients are well-promising, setting the basis for upcoming clinical trials with baroreflex activation on patients with heart failure. However, as the potential therapeutic of BAT unfolds and new perspectives are highlighted, several concerns are raised that should be meticulously addressed before the wide application of this invasive procedure is set in the limelight.
Keywords: Carotid baroreceptor stimulation, baroreflex, hypertension, heart failure, resistant hypertension, heart failure with preserved ejection fraction, sympathetic nervous system.
Current Vascular Pharmacology
Title:Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure
Volume: 12 Issue: 1
Author(s): Doumas M., Faselis C., Kokkinos P., Anyfanti P., Tsioufis C. and Papademetriou V.
Affiliation:
Keywords: Carotid baroreceptor stimulation, baroreflex, hypertension, heart failure, resistant hypertension, heart failure with preserved ejection fraction, sympathetic nervous system.
Abstract: Many difficult-to-treat clinical entities in the cardiovascular field are characterized by pronounced sympathetic overactivity, including resistant hypertension and heart failure, underlining the need to explore therapeutic options beyond pharmacotherapy. Autonomic modulation via carotid baroreceptor activation has already been evaluated in clinical trials for resistant hypertension, and relevant outcomes with regard to safety and efficacy of the technique are critically presented. The pathophysiological background of heart failure renders carotid baroreceptor stimulation a potential treatment candidate for the disease. Available data from animal models with heart failure point towards significant cardioprotective benefits of this innovative technique. Accordingly, the effects of baroreceptor activation treatment (BAT) on cardiac parameters of hypertensive patients are well-promising, setting the basis for upcoming clinical trials with baroreflex activation on patients with heart failure. However, as the potential therapeutic of BAT unfolds and new perspectives are highlighted, several concerns are raised that should be meticulously addressed before the wide application of this invasive procedure is set in the limelight.
Export Options
About this article
Cite this article as:
M. Doumas, C. Faselis, P. Kokkinos, P. Anyfanti, C. Tsioufis and V. Papademetriou, Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990138
DOI https://dx.doi.org/10.2174/15701611113119990138 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Stroke Prevention in Atrial Fibrillation: Concepts and Controversies
Current Cardiology Reviews Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research Calcium Channel Blockers in Restoration of Endothelial Function: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Coronaviruses Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Treatment Considerations of Clinical Physician on Hypertension Management in Asia
Current Hypertension Reviews Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Editorial (Hot Topic: Central Blood Pressure: Current Status and Future Perspective)
Current Hypertension Reviews Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry Vasomotor Effects of Iodinated Contrast Media: Just Side Effects?
Current Vascular Pharmacology Management of Measurable Variable Cardiovascular Disease' Risk Factors
Current Cardiology Reviews Editorial (Thematic Issue: ‘Lone’ Atrial Fibrillation: No Longer Lone or Even Alone)
Current Pharmaceutical Design Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design